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Radioactive Iodine Remnant Ablation: The Beta-knife Completion 
Thyroidectomy
Raydoaktif İyot Bakiye Doku Ablasyonu: Beta-knife Tamamlayıcı Tiroidektomisi
Abstract
The rationale and objectives for radioactive iodine (RAI) ablation remain perplexing to many. This review addresses the 
meaning, clinical context and the goals of “ablation”: the RAI treatment after a total thyroidectomy. This article also aims 
to clarify the definition of a total thyroidectomy and how a thyroid remnant can introduce a confounding factor in the 
postoperative management of patients with differentiated thyroid cancer. The implications of an existing thyroid remnant on 
RAI diagnostic imaging and serum thyroglobulin levels are discussed. This review provides a rational approach validating the 
utility of RAI remnant ablation regardless of the patient’s risk stratification. 
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Öz
Radyoaktif iyot (RAİ) ablasyon kavramı mantığının ve hedeflerinin birçok kişi için hala yeterince açık olmadığını görüyoruz. Bu 
makalede total tiroidektomiyi takiben yapılan RAİ “ablasyon” girişiminin anlamı, hedefleri ve klinik değeri izah edilmektedir. 
Gerçekçi anlamda total tiroidektominin RAİ ablasyonu ile mümkün olduğu tezini savunuyor ve destekleyen verileri sistematik 
olarak sunuyoruz.
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Introduction
The role for radioactive iodine (RAI) in the management 
of metastatic differentiated thyroid cancer (DTC) is 
indisputable. Its utilization postoperatively as part of 
initial treatment, however, is still a matter of debate. The 
2015 American Thyroid Association (ATA) guidelines is a 
133-page document written in a dissertation format (1). 
The rationale for each recommendation is discussed, in 
detail, in a scholarly fashion, but yet, there is a sense of 
ambiguity in defining the indications for administration 
of RAI ablation. This review will discuss the ATA 
recommendations from a perspective that accounts 
surgical considerations, nuclear medicine principles, and 
genomic developments. 
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The Role of RAI (Including Remnant Ablation, 
Adjuvant Therapy, or Therapy for Persistent 
Disease) after Thyroidectomy in the Primary 
Management of Differentiated Thyroid Cancer
RAI treatment is given in three distinct settings with 
different clinical indications (intents); 
1) Ablation of the remnant
2) Adjuvant treatment for residual disease or occult 
metastatic disease
3) Therapy for known metastatic disease.
The term “ablation” specifically refers to first-line RAI 
treatment after surgical total thyroidectomy. 
The specific target of this treatment is normal residual 
thyroid tissue, i.e. the remnant, (Table 1). The confusion 
regarding the indications of RAI ablation stems from the 
underestimation of the impact of the remnant volume and 
patterns of uptake on imaging studies following surgical 
total thyroidectomy. Certain surgical details need to be 
explained in order to clarify the remnant concept from a 
clinical context.
Surgical Anatomy of Total Thyroidectomy, 
Sources and Locations of Thyroid Remnants
The strict definition of total thyroidectomy, as it pertains 
to subsequent diagnostic and therapeutic considerations, 
is the removal of all functioning thyroid tissue. When a 
clinical decision is made for a lobectomy, based on a low 
risk disease designation, “ablation” is not part of the 
equation. Ablation is, in the most simplistic terms, the 
eradication of all functional thyroid tissue left behind 
after surgical total thyroidectomy. A surgical total 
thyroidectomy entails removing the gland in the plane 
outside its “true capsule” (Figure 1). The true capsule 
is a very fine layer. A faithful dissection over the true 
capsule may occasionally pose a significant challenge 
to the viable preservation of the parathyroid glands 
and safe protection of the recurrent laryngeal nerve 
(RLN), as these critical structures have very intimate 
anatomic relations with the true capsule (Figure 2). A 
rational definition of total thyroidectomy is, therefore, 
the removal of the anatomical gland with viable and 
non-traumatic preservation of the parathyroid glands 
and RLN. It is important to emphasize that injuries to 
these critical structures are usually caused by ischemia 
resulting from devascularization, or traumatic contusion 
due to vigorous dissection and traction, not necessarily 
inadvertent transection or resection. A safe dissection, 
when performed in a cognizant way, may result (or even 
require) entering inside the true capsule and leaving a 
focal, thin rim of functional thyroid tissue in situ. A similar 
challenge may be encountered dissecting the upper pole 
vessels. There is an intimate relationship between the 
external branch of the superior laryngeal nerve and the 
superior thyroidal artery and vein. The dissection of the 
thyroid upper pole can also be challenging, particularly 
with a high-riding position. A safe division of the upper 
pole vasculature could leave behind a small remnant 
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Table 1. Radioactive iodine treatment objectives
RAI treatment 
intent
Target Objectives
Ablation Remnant Increase specificity of 
Tg monitoring
Complete post-
surgical staging
Identify/clear 
ambiguous foci of 
uptake
Adjuvant treatment Residual disease
Recurrent disease
Metastatic disease
Ablation objectives
Disease control
Therapy Residual disease
Recurrent disease
Metastatic disease
Disease control
RAI: Radioactive iodine, Tg: Thyroglobulin
2015 ATA Recommendation 51
A) RAI remnant ablation is not routinely recommended 
after thyroidectomy for ATA low-risk DTC patients. 
Consideration of specific features of the individual 
patient that could modulate recurrence risk, disease 
follow-up implications, and patient preferences 
are relevant to RAI decision-making (Weak 
recommendation, low-quality evidence).
B) RAI remnant ablation is not routinely recommended 
after lobectomy or total thyroidectomy for patients 
with unifocal papillary microcarcinoma, in the absence 
of other adverse features (Strong recommendation, 
moderate-quality evidence).
C) RAI remnant ablation is not routinely recommended 
after thyroidectomy for patients with multifocal 
papillary microcarcinoma in the absence of other 
adverse features. Consideration of specific features of 
the individual patient that could modulate recurrence 
risk, disease follow-up implications, and patient 
preferences are relevant to RAI decision-making (Weak 
recommendation, low-quality evidence).
D) RAI adjuvant therapy should be considered after 
total thyroidectomy in ATA intermediate-risk level 
DTC patients (Weak recommendation, low-quality 
evidence).
E) RAI adjuvant therapy is routinely recommended 
after total thyroidectomy for ATA high-risk DTC 
patients (Strong recommendation, moderate-quality 
evidence).
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Figure 1. The surgical anatomy and technique of total thyroidectomy, remnant volume. This diagram adapted from Tan et al. (7) shows the fascial 
compartments in the thyroid space. The parathyroid glands are situated over the true capsule. The separation of the parathyroid glands off the true capsule 
can disrupt the vascular supply. The cranial end of the recurrent laryngeal nerve typically travels under the ligament of Berry and, at this position, is very 
close to the true capsule of the thyroid. A vigorous extracapsular dissection may traumatize these vital structures even if they are carefully identified and 
avoided during surgery
Figure 2. The image on the left shows a parathyroid gland lying on the thyroid capsule. The image on the right shows the recurrent laryngeal nerve under 
the ligament of Berry, and their very intimate relations with the true capsule of the thyroid gland
19
(Figure 3). The pyramidal lobe usually has a short 
extension containing functional tissue that becomes a 
fibrotic cord as it extends cranially. It is typically divided 
at a reasonable length along its tract. Occasionally this 
pyramidal cord may also contain functioning thyroid 
tissue. The totality of a total thyroidectomy is reliant 
on the surgeon’s technique. High volume experienced 
surgeons can produce consistent results in terms of low 
remnant volume; however, the reality in community 
settings could vary widely. The terms near-total or sub-
total thyroidectomy are disclosures of not insignificant 
remnant volume. Remnant thyroidectomy is accomplished 
by RAI ablation.
Radioactive Iodine Ablation: Beta-knife 
Completion Thyroidectomy
The therapeutic effect of I-131 works through beta 
particles, thus, it has been named a “beta-knife” (2). 
The objectives of ablation are three-fold a) Ablation 
eradicates all functioning thyroid tissue. With that goal 
accomplished, thyroglobulin (Tg) becomes a highly 
specific tumor marker. This simply facilitates the post-
op long-term patient follow-up. b) Ablation wipes out 
all focal normal thyroid tissue left in-situ by the surgeon 
to avoid injury to laryngeal nerves and parathyroid 
glands. From a surgical standpoint, these small clusters 
of normal thyroid tissue remnants are inconsequential; 
however, they appear as focal areas of RAI uptake on 
future imaging studies and can easily be interpreted as 
metastatic disease. Eradication of these potential sources 
of misdiagnosis, while there is still open communication 
between the surgeon and the imager, is important. c) The 
post-ablation whole-body scan is considered the standard 
for extent of disease evaluation. 
When postoperative RAI treatment is contemplated with 
an adjuvant intent, in addition to the remnant ablation 
objectives, RAI is aimed to target residual disease or occult 
metastatic disease. When the intent is adjuvant treatment, 
risk stratification becomes important in the selection of 
the administered activity of I-131. For remnant ablation 
purposes only, the risk stratification has no bearing. 
Complete thyroidectomy, in the strictest sense, is only 
possible with surgical (cold steel knife) thyroidectomy, 
followed by I-131 ablation (beta knife). There exists a group 
of patients where surgical total thyroidectomy removes 
all the functional remnant tissue. Although it could be 
argued that RAI ablation is not necessary in this group, it is 
challenging to identify these patients using standard clinical 
evaluations.
Challenges and Potential Solutions for Accurate 
Assessment of Remnant Volume
The volume of the thyroid remnant is highly variable 
and is dependent on the surgeon’s technique; it is not 
typically highlighted in the operative report and is usually 
undetectable by ultrasound (US) or other anatomic imaging 
modalities such as computed tomography (CT) or magnetic 
resonance imaging (MRI). Serum Tg can provide some 
information as to the presence of functioning thyroid 
tissue; but the marked variability in Tg levels, which can 
overlap with metastatic disease, makes Tg an unreliable 
quantitative measure of remnant volume. Occult metastatic 
sites may only be detected by a post-ablation scan. Typical 
1-5 mCi I-131 imaging has notoriously low sensitivity for 
disclosing occult foci.
Postoperative/pre-ablative RAI imaging may be 
considered to determine the extent of residual functional 
thyroid tissue, or remnant volume. I-131 has become 
the mainstay for RAI imaging due to its availability and 
relatively low cost; however, one must recognize the 
inherent limitations of I-131 as a diagnostic imaging 
agent. I-131 has high energy gamma emissions with 
the greatest abundance of 364 keV which lead to septal 
penetration and limit the spatial resolution of standard 
gamma cameras. In addition, only low administered 
activities of I-131 can be given for diagnostic purposes 
due to concerns for stunning, especially when subsequent 
RAI treatment is being considered. Routine diagnostic 
I-131 scans are usually performed with administered 
activities in the range of 1-5 mCi. These low dose 
images are often of limited diagnostic quality and may 
underestimate the extent of disease evaluation. Subtle 
or non-visualized foci of RAI avid disease on low dose 
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Figure 3. Normal postoperative radioactive iodine scan. This image shows 
a small focus of activity at the midline of the lower neck compatible with a 
midline remnant. There are also two small foci of radioactive iodine uptake in 
the upper neck, which are equivocal. Upon referring with the surgeon who 
performed the operation, these foci were confirmed to represent remnant 
activity beneath the superior parathyroid glands. Without knowledge of the 
operative findings these can easily be reported as metastatic nodal disease
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diagnostic I-131 scans may become evident on post-
treatment scans with therapeutic administered activities 
(Figure 4). Even with higher administered activities of 
I-131, it can be difficult to differentiate foci of uptake 
in the neck as thyroid remnants versus nodal metastatic 
disease. RAI avid foci in the neck can be elucidated with 
increased confidence only after the thyroid remnant has 
been completely ablated. In addition, eliminating the 
remnant comprised of highly avid normal thyroid tissue 
reduces competition for RAI at metastatic sites thereby 
enhancing diagnostic scan sensitivity and therapeutic 
efficacy (3).
Although not in routine clinical use currently, I-124 imaging 
has been demonstrated to be a very sensitive functional 
imaging agent. I-124 positron emission tomography (PET)/
CT has an outstanding spatial resolution in elucidating 
small thyroid remnants from the right or left lobes or in 
the distribution of the pyramidal lobe (Figure 5). Due to 
its anatomic precision, I-124 PET/CT can also distinguish 
nodal uptake from a remnant in the thyroid bed which may 
not be adequately visualized with other imaging modalities. 
I-124 has been shown to have a similar performance in 
detection of RAI avid lesions as compared to post-
therapeutic I-131 scans. Additionally, the risk of stunning at 
higher administered activities of I-131 may not be observed 
with I-124. Therefore, I-124 may be considered the most 
sensitive imaging modality for assessing remnant thyroid 
tissue.
Perhaps the greatest merit of I-124 PET/CT is that it allows 
accurate quantitation of remnant volume and kinetics for 
the purposes of remnant dosimetry. Our group showed 
significant variations in cumulated activities and functional 
volumes of thyroid remnants between cohort patients. 
The maximum remnant activity ranged from 1.2 to 215.9 
uCi with the total functional remnant volume (the total 
number of voxels within the remnant range of interest) 
ranging from 1 to 60 mL. The activity per volume of 
remnant tissue ranged from 0.036 to 11.265 uCi/mL. The 
total cumulated activity within the remnant ranged from 
68 to 12757.3 uCi/hr (4). This variability highlights how 
a thyroid remnant may become a confounding factor in 
the postoperative management of DTC patients and why 
RAI ablation is key to maintaining a standard baseline for 
which future imaging and laboratory parameters can be 
compared.
Specificity of Thyroglobulin
Tg is a highly specific tumor marker when functioning 
thyroid tissue is no longer present, i.e. after total 
thyroidectomy and RAI ablation of the remnant. It has 
been estimated that 1 g of normal thyroid tissue releases 
about 1 ng/mL of Tg into the serum when thyroid-
stimulating hormone (TSH) is normal and about 0.5 ng/
mL when TSH is suppressed (<0.1 mIU/L) (5). The remnant 
volume, and thus remnant-produced Tg, is dependent on 
the surgical technique and potentially could be highly 
variable/unpredictable. 
The factors influencing baseline and recombinant human 
TSH stimulated Tg levels in patients with metastatic DTC 
were investigated in a study by Robbins et al. (6). The 
authors found wide variations in Tg levels and considerable 
overlap between metastatic sites. The median baseline Tg 
level for cervical metastases was 2 ng/mL and increased 
to a median of 8 ng/mL after recombinant human TSH 
stimulation. The median baseline and stimulated Tg levels 
for mediastinal metastases were 4 ng/mL and 16 ng/mL, 
and for distant metastatic sites were 25 ng/mL and 180 
ng/mL, respectively. The patients with thyroid remnants 
included in the study had a median baseline Tg level of 
0.6 ng/mL, with the highest being 66 ng/mL. After 
recombinant human TSH, the median stimulated Tg in 
patients with thyroid remnants was 1.2 ng/mL but ranged 
as high as 250 ng/mL.
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Figure 4. Radioactive iodine (RAI) scan with 1 mCi versus 100 mCi 
demonstrating occult remnant or nodal disease. The image on the left is 
a diagnostic whole body scan with 1 mCi of I-131 showing no abnormal 
RAI avid foci in the neck. The image on the right is a posttreatment scan 
for the same patient after therapy with 100 mCi of I-131. This image shows 
physiologic activity in the salivary glands as well as two RAI avid foci in the 
neck that were confirmed to represent nodal metastases
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Following Tg levels in patients who have undergone 
total thyroidectomy but not RAI ablation is challenging. 
The Tg level is expected to increase by at least two-
fold in the presence of a thyroid remnant under the 
influence of recombinant human TSH; however, the 
stimulated Tg level has been shown to increase almost 
four-fold in some patients. The inconsistent baseline 
Tg levels produced by the remnant along with the 
documented variability in stimulated Tg levels that 
overlap with metastatic disease make it very difficult to 
reliably detect occult metastasis. In addition, the natural 
progression of an un-ablated thyroid remnant under 
TSH suppression and its effect on Tg production are not 
clearly established. These issues can be avoided if the 
thyroid remnant is ablated with RAI thereby eradicating 
all functioning thyroid tissue and rendering Tg a very 
specific indicator of recurrent disease in post-surgical 
patients.
The Activity of I-131 to be Used for Remnant 
Ablation or Adjuvant Therapy 
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Figure 5. I-124 positron emission tomography/computed tomography image through the level of the thyroid bed shows regions of interest drawn around 
a thyroid remnant (blue) and a metastatic right level 3 lymph node (green). The remnant is not measurable by ultrasound or computed tomography. There 
is overestimation of functional volume (correctible) due to voxel saturation phenomenon
2015 ATA Recommendation 55
A) If RAI remnant ablation is performed after total 
thyroidectomy for ATA low-risk thyroid cancer or 
intermediate-risk disease with lower risk features 
(i.e., low-volume central neck nodal metastases with 
no other known gross residual disease or any other 
adverse features), a low administered activity of 
approximately of 30 mCi is generally favored over higher 
administered activities (Strong recommendation, high-
quality evidence).
B) Higher administered activities may need to be 
considered for patients receiving less than a total or 
near-total thyroidectomy in which a larger remnant 
is suspected or in which adjuvant therapy is intended 
(Weak recommendation, low-quality evidence).
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Currently, the most common practice in RAI ablation 
is to use a fixed amount of radioiodine regardless of 
the size of the thyroid remnant or the percentage of 
radioiodine uptake. Different administered activity levels 
have been tested over the years ranging from 30 mCi to 
150 mCi. There has been a paradigm shift towards using 
less administered activities for RAI remnant ablation 
in the setting of low-risk DTC since the publication of 
two high-impact articles in the New England Journal of 
Medicine in 2012, and further propagated after release 
of the 2015 ATA guidelines (8,9). As paradoxical as it 
may seem, 30 mCi of radioiodine will completely destroy 
the thyroid remnant in some patients whereas 150 mCi 
may not be sufficient in others. The explanation is that, 
there is no linear relationship between the administered 
activity and radiation absorbed dose to the remnant. The 
radiation dose (in rads) depends not only on the number 
of millicuries administered, but also the percent uptake, 
the size of the remnant, and the effective half-life (T1/2 
eff) of I-131 in the remnant. Patients with small remnants 
and high uptakes may receive a large radiation dose from 
30 mCi whereas those with large remnants and low 
uptakes may receive a small and inadequate radiation 
dose from 150 mCi. In a 1983 dosimetric study, Becker 
and Hurley demonstrated a wide variation in uptake and 
remnant size in patients who were referred for ablation 
(10). There was no correlation between the number of 
millicuries administered and the radiation absorbed dose 
delivered to the remnant (Figure 6). Although this study 
unarguably demonstrated the unreliability of a fixed 
or standard amount of radioiodine for ablation, due 
to feasibility and logistical considerations a dosimetric 
approach never was adapted. 
There is a clear need to develop individualized dosimetry-
guided RAI ablation protocols. I-124 PET/CT offers a 
robust quantitative tool to achieve this goal. Active 
studies are being performed to determine the technical 
prerequisites for a time and cost-conscious standard 
protocol.
Summary and Recommendations
Although the potential side effects of RAI are real 
and efforts to utilize lower administered activities for 
ablation are commendable, this should not overlook the 
opportunity for achieving complete ablation. The benefits 
of complete remnant ablation in the future follow-up 
and management of DTC patients after thyroidectomy 
cannot be denied. From a practical standpoint, a total 
thyroidectomy usually leaves behind some functioning 
thyroid tissue. This postsurgical thyroid remnant cannot 
be accurately evaluated/visualized with anatomic imaging 
studies like CT or ultrasound, and it can be misleading 
on functional RAI imaging indistinguishable from RAI avid 
disease in the neck. Moreover, the volume of remaining 
thyroid tissue is dependent upon the surgical technique 
and invariably and unpredictably affects the Tg level 
at baseline and under TSH stimulation. Avoiding RAI 
remnant ablation because of the risk of side effects or 
the reliance on underpowered, short-term prospective 
studies or flawed retrospective analyses fails to recognize 
the goals of therapy and the practical approach to the 
postoperative follow-up of DTC patients. The therapeutic 
administration of RAI to ablate the thyroid remnant allows 
for completion of a “true” total thyroidectomy (cold 
steel knife + beta knife) and improves the postoperative 
management of DTC patients by facilitating RAI imaging 
and permitting the use of serum Tg as a highly specific 
tumor marker. 
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2015 ATA Recommendation 56
Administered RAI Activity (mCi) and Radiation 
Absorbed Dose (Rad) Relationship
When RAI is intended for initial adjuvant therapy 
to treat suspected microscopic residual disease, 
administered activities above those used for remnant 
ablation up to 150 mCi are generally recommended (in 
absence of known distant metastases). It is uncertain 
whether routine use of higher administered activities 
(>150 mCi) in this setting will reduce structural 
disease recurrence for T3 and N1 disease (Weak 
recommendation, low-quality evidence).
Figure 6. Lack of correlation between radiation dose to the remnant and 
millicuries of radioactive iodine administered. Adapted from (10) Hurley JR, 
Becker DV. The use of radioiodine in the management of thyroid cancer. 
Freeman LM, Weissman HS (eds). Nuclear Medicine Annual. New York, 
Raven Press 1983;329-384.
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The recommendations below incorporate genomic 
profiling for risk stratification and dosimetric approach 
for selection of administered activities for RAI ablation.
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Proposed Guidelines for RAI Ablation
A) RAI ablation decision should be made at the time 
of the surgical treatment decision. Risk stratification 
should include genomic profiling. RAI remnant ablation 
is routinely recommended after total thyroidectomy, 
if the preoperative intent was total elimination 
of anatomic and functional thyroid tissue. Main 
consideration is the role for Tg monitoring and RAI 
imaging surveillance in the long-term management 
of patients. RAI ablation should be administered 
with radiation absorbed dose to the remnant tissue 
optimized.
B) If micropapillary cancer was incidentally 
reported in the surgical pathology following a total 
thyroidectomy, RAI ablation may be omitted if there is 
no histopathologic or genomic risk factor identified.
C) RAI remnant ablation is not indicated after 
lobectomy. If a histopathologic or genomic risk factor 
is identified, a completion thyroidectomy should be 
performed and followed by RAI ablation.
D) If the clinical intent is adjuvant treatment for 
suspected/known residual/metastatic disease RAI 
ablation should be administered in a therapeutic 
context, with radiation absorbed dose to the malignant 
disease optimized.
E) Administered activity selection should be 
determined based on dosimetric considerations, 
for both remnant ablation and adjuvant treatment 
indications.
